| Date Filed | Type | Description |
| 09/29/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/15/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 08/14/2023 |
4
| Shoemaker Mary Teresa (Director) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Granted 66,468 options to buy
@ $1.02, valued at
$67.8k
|
|
| 08/14/2023 |
4
| STOVER JACK E (Director) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Granted 66,468 options to buy
@ $1.02, valued at
$67.8k
|
|
| 08/14/2023 |
4
| Atadja Peter (Director) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Granted 66,468 options to buy
@ $1.02, valued at
$67.8k
|
|
| 08/14/2023 |
4
| Clarke Trafford (Director) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Granted 66,468 options to buy
@ $1.02, valued at
$67.8k
|
|
| 08/14/2023 |
4
| MEHTA VIREN (Director) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Granted 66,468 options to buy
@ $1.02, valued at
$67.8k
|
|
| 08/14/2023 |
4
| GROOPMAN JEROME (Director) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Granted 66,468 options to buy
@ $1.02, valued at
$67.8k
|
|
| 08/14/2023 |
4
| MARINO JAMES J (Director) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Granted 66,468 options to buy
@ $1.02, valued at
$67.8k
|
|
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
4
| Guerin Mark Patrick (CFO AND COO) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,422 shares
@ $1.02, valued at
$1.5k
Exercised 4,750 restricted stock units
@ $0 |
|
| 08/04/2023 |
4
| Fruchtman Steven M (PRESIDENT, CHIEF EXECUTIVE OFF) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 4,744 shares
@ $1.01, valued at
$4.8k
Exercised 12,567 restricted stock units
@ $0 |
|
| 07/21/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/12/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/30/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 06/07/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 06/07/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results |
| 05/09/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/16/2023 |
8-K
| Quarterly results |
| 03/14/2023 |
4
| Guerin Mark Patrick (CFO AND COO) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Granted 79,000 options to buy
@ $0.73, valued at
$57.7k
Granted 26,000 restricted stock units
@ $0 |
|
| 03/14/2023 |
4
| Fruchtman Steven M (PRESIDENT, CHIEF EXECUTIVE OFF) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Granted 207,000 options to buy
@ $0.73, valued at
$151.1k
Granted 69,333 restricted stock units
@ $0 |
|
| 03/14/2023 |
4
| Gelder Mark S. MD (CHIEF MEDICAL OFFICER) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Granted 62,000 options to buy
@ $0.73, valued at
$45.3k
Granted 20,667 restricted stock units
@ $0 |
|
| 02/13/2023 |
8-K
| Quarterly results |
| 02/08/2023 |
4
| Fruchtman Steven M (PRESIDENT, CHIEF EXECUTIVE OFF) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 6,977 shares
@ $1.36, valued at
$9.5k
Exercised 21,320 restricted stock units
@ $0 |
|
| 02/08/2023 |
4
| Gelder Mark S. MD (CHIEF MEDICAL OFFICER) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,242 shares
@ $1.36, valued at
$1.7k
Exercised 5,833 restricted stock units
@ $0 |
|
| 02/08/2023 |
4
| Guerin Mark Patrick (CFO AND COO) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,785 shares
@ $1.36, valued at
$2.4k
Exercised 6,900 restricted stock units
@ $0 |
|
| 12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/19/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
|